Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
External Resources
Posted by 
Last updated and reviewed on: December 10, 2025What is CAR T-cell therapy for lymphoma?
When to consider CAR T-cell therapy?
FDA-approved lymphoma CAR T-cell therapies
- Yescarta Prescribing Information
- Breyanzi Prescribing Information
- Kymriah Prescribing Information
- Tecartus Prescribing Information
- Receiving YESCARTA
- How will I receive BREYANZI?
- What to Expect With KYMRIAH
- Boom-Boom Radiation as Bridging Therapy Prior to CAR-T for DLBCL
- Optimizing bridging therapy before CAR-T in patients with lymphoma
- A promising step for high-risk FL
- Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
- Kymriah Efficacy
- Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
- Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Side effect management of CAR T-cell therapy for lymphoma
- Cytokine release syndrome
- Grading of cytokine release syndrome associated with the CAR T cell therapy
- Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
- CAR T-Cell Grading and Management: ICANS
- In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
- Cytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem
- Managing Fatigue, Anemia, and GI Side Effects with Nutrition
- Cytopenia
- Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy
- Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies
- Immune effector cell-associated neurotoxicity syndrome (ICANS) and other neurologic toxicities of CAR-T cell and related therapies
- Prolonged Cytopenia with CAR-T Cell Therapy and Management Recommendations
- Potential Side Effects of CAR T-cell Therapy: Symptoms & Treatment
- New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies
- Nausea and vomiting